Intended for U.S. healthcare professionals only.
For corporate information, please visit Mallinckrodt.com.
Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses.
Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects. The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. Naltrexone does not appear to be a hepatotoxin at the recommended doses.
Patients should be warned of the risk of hepatic injury and advised to stop the use of naltrexone and seek medical attention if they experience symptoms of acute hepatitis.
|Description||Yellow, Film Coated Capsule-Shaped Tablet|
|Dosage Strength||50 mg|
|Identification Code||Debossed with a number "50" and a full bisect in between the 5 and 0 on one side and "1170" on the other side|
|NDC #||Package Size||Case Quantity|
For additional information on Naltrexone HCl Tablets, USP 50 mg, call Customer Service at 1.800.325.8888 or Medical Information at 1.800.778.7898.